See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Xin Han Zhao
First Affiliated Hospital of Medical School of Xi'an jiaotong University
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Human CD133+ hematopoietic progenitor cells (HPCs) are a specific subset of cells that can regulate tumor malignancy. However, the mechanism by which CD133+ HPCs affect the malignancy of human breast cancer has not been reported.
Methods: CD133+ HPCs were isolated and purified from human umbilical cord blood (UCB) .We used in vitro culture of MCF-7 and MDA-MB-231 cell lines, and MCF-7 and MDA-MB-231 cells in nude mice to evaluate whether CD133+ HPCs affected the apoptosis, proliferation, invasion and epithelial mesenchymal transition EMT of breast cancer cells.
Results: Co-culture with CD133+ HPCs, but not UCB CD133- cells, promoted the proliferation of human breast cancer MCF-7 and MDA-MB-231 cells, accompanied by reducing in vitro spontaneous apoptosis. Co-administration of these two lines with CD133+ HPCs significantly enhanced the growth of implanted breast cancer in vivo. Furthermore, co-culture with CD133+ HPCs, enhanced the invasion of breast cancer cells, N-cadherin and Vimentin expression, but reduced E-cadherin expression in breast cancer cells.
Conclusions: Our study demonstrated that CD133+ HPCs enhance the malignancy of breast cancer cells by attenuating spontaneous apoptosis and promoting the process of epithelial mesenchymal transition. These findings may provide new insights into the role of human CD133+ HPCs in breast cancer pathogenesis. Therefore, CD133+ HPCs may be a new therapeutic target for inhibiting the progression of breast cancer.
Keywords
CD133, hematopoietic progenitor cells, breast cancer cells, malignancy
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
- SupplementaryMaterials.pdf
Revision Figure 1: CD133+ HPCs enhance breast cancer cell proliferation and attenuates apoptosis in vitro.Different cell ratios of MCF-7/MDA-MB-231 breast cancer cell versus CD133+ HPCs from 40:1, 30:1, 20:1 to 10:1 were tested and identified 20:1 gave the most profound effect towards proliferation and apoptosis of cancer cells. *P< 0.05, compared with 40:1, 30:1 and 10:1 group. Revision Figure 2: CD133+ HPCs enhance breast cancer cell invasion in vitro. Different cell ratios of MCF-7/MDA-MB-231 breast cancer cell versus CD133+ HPCs from 40:1, 30:1, 20:1 to 10:1 were tested and identified 20:1 gave the most profound effect towards invasion of cancer cells. *P< 0.05, compared with 40:1, 30:1 and 10:1 group.
- NC3RsARRIVEGuidelinesChecklistfillable.pdf
- Figure5Originalpicture.docx
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 18 Nov, 2020
Editorial decision: Accept
On 11 Nov, 2020
Version 3
Posted 23 Oct, 2020
No comments provided
Editorial decision: Minor revision
On 08 Nov, 2020
Reviewer #1 agreed
On 23 Oct, 2020
Review #1 received
Received 23 Oct, 2020
Reviewers invited
Invitations sent on 23 Oct, 2020
Editor assigned
On 13 Oct, 2020
Submission checks complete
On 12 Oct, 2020
Editor invited
On 12 Oct, 2020
No comments provided
Review #1 received
Received 04 Oct, 2020
Reviewer #2 agreed
On 18 Sep, 2020
Reviewers invited
Invitations sent on 17 Sep, 2020
Reviewer #1 agreed
On 17 Sep, 2020
Editor assigned
On 08 Sep, 2020
Submission checks complete
On 07 Sep, 2020
Editor invited
On 07 Sep, 2020
No comments provided
Review #2 received
Received 19 Jul, 2020
Editorial decision: Major revision
On 19 Jul, 2020
Review #1 received
Received 08 Jun, 2020
Reviewer #2 agreed
On 01 Jun, 2020
Reviewer #1 agreed
On 13 May, 2020
Editor assigned
On 01 May, 2020
Reviewers invited
Invitations sent on 01 May, 2020
Submission checks complete
On 30 Apr, 2020
Editor invited
On 30 Apr, 2020
First submitted
On 27 Apr, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Xin Han Zhao
First Affiliated Hospital of Medical School of Xi'an jiaotong University
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 18 Nov, 2020
Editorial decision: Accept
On 11 Nov, 2020
Version 3
Posted 23 Oct, 2020
No comments provided
Editorial decision: Minor revision
On 08 Nov, 2020
Reviewer #1 agreed
On 23 Oct, 2020
Review #1 received
Received 23 Oct, 2020
Reviewers invited
Invitations sent on 23 Oct, 2020
Editor assigned
On 13 Oct, 2020
Submission checks complete
On 12 Oct, 2020
Editor invited
On 12 Oct, 2020
No comments provided
Review #1 received
Received 04 Oct, 2020
Reviewer #2 agreed
On 18 Sep, 2020
Reviewers invited
Invitations sent on 17 Sep, 2020
Reviewer #1 agreed
On 17 Sep, 2020
Editor assigned
On 08 Sep, 2020
Submission checks complete
On 07 Sep, 2020
Editor invited
On 07 Sep, 2020
No comments provided
Review #2 received
Received 19 Jul, 2020
Editorial decision: Major revision
On 19 Jul, 2020
Review #1 received
Received 08 Jun, 2020
Reviewer #2 agreed
On 01 Jun, 2020
Reviewer #1 agreed
On 13 May, 2020
Editor assigned
On 01 May, 2020
Reviewers invited
Invitations sent on 01 May, 2020
Submission checks complete
On 30 Apr, 2020
Editor invited
On 30 Apr, 2020
First submitted
On 27 Apr, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background: Human CD133+ hematopoietic progenitor cells (HPCs) are a specific subset of cells that can regulate tumor malignancy. However, the mechanism by which CD133+ HPCs affect the malignancy of human breast cancer has not been reported.
Methods: CD133+ HPCs were isolated and purified from human umbilical cord blood (UCB) .We used in vitro culture of MCF-7 and MDA-MB-231 cell lines, and MCF-7 and MDA-MB-231 cells in nude mice to evaluate whether CD133+ HPCs affected the apoptosis, proliferation, invasion and epithelial mesenchymal transition EMT of breast cancer cells.
Results: Co-culture with CD133+ HPCs, but not UCB CD133- cells, promoted the proliferation of human breast cancer MCF-7 and MDA-MB-231 cells, accompanied by reducing in vitro spontaneous apoptosis. Co-administration of these two lines with CD133+ HPCs significantly enhanced the growth of implanted breast cancer in vivo. Furthermore, co-culture with CD133+ HPCs, enhanced the invasion of breast cancer cells, N-cadherin and Vimentin expression, but reduced E-cadherin expression in breast cancer cells.
Conclusions: Our study demonstrated that CD133+ HPCs enhance the malignancy of breast cancer cells by attenuating spontaneous apoptosis and promoting the process of epithelial mesenchymal transition. These findings may provide new insights into the role of human CD133+ HPCs in breast cancer pathogenesis. Therefore, CD133+ HPCs may be a new therapeutic target for inhibiting the progression of breast cancer.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
This is a list of supplementary files associated with this preprint. Click to download.
- SupplementaryMaterials.pdf
Revision Figure 1: CD133+ HPCs enhance breast cancer cell proliferation and attenuates apoptosis in vitro.Different cell ratios of MCF-7/MDA-MB-231 breast cancer cell versus CD133+ HPCs from 40:1, 30:1, 20:1 to 10:1 were tested and identified 20:1 gave the most profound effect towards proliferation and apoptosis of cancer cells. *P< 0.05, compared with 40:1, 30:1 and 10:1 group. Revision Figure 2: CD133+ HPCs enhance breast cancer cell invasion in vitro. Different cell ratios of MCF-7/MDA-MB-231 breast cancer cell versus CD133+ HPCs from 40:1, 30:1, 20:1 to 10:1 were tested and identified 20:1 gave the most profound effect towards invasion of cancer cells. *P< 0.05, compared with 40:1, 30:1 and 10:1 group.
- NC3RsARRIVEGuidelinesChecklistfillable.pdf
- Figure5Originalpicture.docx
Loading...